Randomized Double Blind Clinical Study Shows Improvement for 90% of Fibromyalgia Patients Using Swiss Medica's O24 Pain Relief Product.

TORONTO -- Pursuant to the Company's December 22nd (2004) News Release, Swiss Medica (OTCBB:SWME) is pleased to announce the results of the randomized double blind clinical trial conducted during the fourth quarter, comparing the Company's O24 pain reliever against a placebo on patients suffering from fibromyalgia.

Dr. Gordon Ko (Head, Fibromyalgia clinic) and Dr. David Berbrayer (Head, Dept. Rehabilitation Medicine) at Sunnybrook & Women's Health Sciences Centre (University of Toronto), directed this 4-6 week pilot study of 153 fibromyalgia subjects. Of these, 133 participants (87%) completed the study with 68 (51%) using a placebo. The other 65 (49%) used the O24 product. Assessments of these participants were carried out at multiple community clinics in the Greater Toronto Area.

"The group treated with O24 compared to placebo showed statistically significant improvement when measured on the Visual Analog Scale for pain," announced Dr. Gordon Ko, who is also the Medical Director for the Canadian Centre for Integrative Medicine in Markham, Ontario. Dr. Ko's clinical study was statistically peer-reviewed by Marko Katic, biostatistician at the Institute of Clinical Evaluative Studies (ICES). Dr. Ko has submitted his findings to a peer-reviewed medical journal for publication.

Improvement was also statistically significant for VAS night pain, Jamar hand-grip strength, total number of fibromyalgia tender points and the average tender point pain threshold as measured by algometry. For participants who used O24, more than 90% of the patients reported mild to markedly better improvement on the 7-point Lanier rating scale. Nearly 54% reported moderately better or markedly better results using O24 instead of the placebo. About 80% of the placebo group reported no change in their condition and 13% reported a worsening of their condition. Only 7% reported mild improvement from the placebo.

Dr. Ko concluded about O24, "With the demise of traditional medications, such as the Cox-2 inhibitors, the use of therapies that have such clinical effectiveness, and minimal to insignificant side effects, is exciting news."

Swiss Medica's President, Grant Johnson announced, "This is a landmark certification for Swiss Medica and a superlative confirmation for the performance of the company's O24 product in reducing pain. With the significant discovery that more than 90% of the patients who improved, using our O24 pain relief product, compared to only 7% who experienced mild improvement using the placebo, this clinical trial clearly confirms that O24 provides an outstanding efficacy in pain management therapy. Based upon these clinical results, we will move forward with our plans to launch O24 Fibromyalgia in Q3 designed for those that suffer from this serious condition. Our next phase will include a longer, placebo-controlled crossover clinical study with a larger patient base and multi-site studies, which we will announce at the appropriate time."

At present, there are no medications approved by the U.S. Food and Drug Administration (FDA) for treating fibromyalgia, a common and chronic disorder characterized by widespread muscle pain, fatigue, and multiple tender points. According to the National Fibromyalgia Association, "It is estimated that approximately 3-6% of the U.S. population has fibromyalgia." Based upon the latest expert estimates, fibromyalgia may affect between 8 million and 17 million Americans.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Swiss Medica Inc. (OTC Bulletin Board:SWME)